Huntington Disease CRISPR Cell Models for Drug Discovery

Huntington disease (HD) is a rare, autosomal dominant neurodegenerative disorder with a global prevalence of approximately 2.7 per 100,000 (WHO, 2023). Onset typically occurs between 30-50 years of age, with a median survival of 15-20 years after symptom onset. The disease is characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances. There is no cure, and current treatments only manage symptoms. The economic burden is substantial, with annual costs per patient exceeding $25,000 in the US (NCI, 2023).

HD is ideal for mechanistic studies due to its monogenic cause: a CAG trinucleotide repeat expansion in the HTT gene. This clear genetic origin allows precise modeling in cell lines. Key research questions include understanding the threshold of CAG repeats (typically >36) for disease manifestation, the role of mutant huntingtin protein aggregation, and the selective vulnerability of striatal neurons. Public datasets, such as those from the HD iPSC Consortium and the ENCODE project, provide rich resources for transcriptomic and proteomic analyses.

The mutant huntingtin protein (mHTT) disrupts multiple cellular processes:

1. Transcriptional Dysregulation: mHTT interacts with transcription factors (e.g., CREB, Sp1), leading to reduced expression of neurotrophic factors like BDNF.

2. Proteostasis Impairment: mHTT aggregates inhibit the ubiquitin-proteasome system and autophagy, causing accumulation of damaged proteins.

3. Mitochondrial Dysfunction: mHTT impairs mitochondrial trafficking and oxidative phosphorylation, increasing reactive oxygen species (ROS).

4. Excitotoxicity: mHTT sensitizes neurons to glutamate-induced excitotoxicity via NMDA receptor modulation.

Data from ClinVar and NCBI Gene. Unlike cancer, HD is not characterized by somatic mutations in multiple genes; the HTT expansion is the primary driver.

• • BDNF/TrkB Pathway: Reduced BDNF transcription leads to decreased neuronal survival.
• • mTOR Pathway: Hyperactivation of mTOR due to impaired autophagy contributes to aggregate accumulation.
• • p53 Pathway: mHTT stabilizes p53, promoting apoptosis.
• • Wnt/β-catenin Signaling: Disrupted in HD, affecting neurogenesis and synaptic plasticity.

Organoids derived from HD patient iPSCs recapitulate cortical and striatal development, enabling study of early pathogenic events.

• • R6/2 Mouse: Expresses exon 1 of human HTT with ~150 CAG repeats; rapid phenotype (motor deficits by 5-6 weeks).
• • YAC128 Mouse: Expresses full-length human HTT with 128 CAG repeats; slower progression.
• • BACHD Mouse: Expresses full-length human HTT with 97 CAG repeats; exhibits motor and cognitive deficits.
• • zQ175 Mouse: Knock-in model with ~190 CAG repeats; shows progressive HD-like symptoms.
• • Non-human primate models: Transgenic monkeys expressing mHTT; more closely recapitulate human pathology.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with defined HTT CAG repeat lengths. For example, knock-in of expanded CAG repeats into HEK293T or SH-SY5Y cells creates models with specific repeat numbers (e.g., 40, 50, 100). Conversely, CRISPR knockout of HTT in patient-derived cells can model loss-of-function effects. These sequence-verified, commercially available models allow precise control over genetic background, eliminating confounding factors. They are essential for studying repeat length-dependent toxicity and for screening therapeutic compounds.

CRISPR knockout of HTT in isogenic lines validates the necessity of the protein for cellular processes. For example, HTT knockout in HEK293T cells reveals its role in vesicular trafficking and ciliogenesis. Knock-in of expanded repeats allows dose-response studies of CAG repeat length on aggregation and toxicity.

Isogenic pairs (e.g., wild-type vs. HTT-Q100) are used in high-throughput screens to identify compounds that reduce mHTT aggregation or toxicity. Resistance mechanisms can be modeled by exposing cells to candidate drugs and selecting for resistant clones, then sequencing to identify compensatory mutations.

CRISPR-based synthetic lethality screens in HD cell models identify genes whose knockdown selectively kills mHTT-expressing cells. This approach has revealed potential therapeutic targets such as the autophagy regulator ATG5 and the chaperone HSP90.